A comprehensive view of Merck & Co. Inc.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your R&D/Patents Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Merck to acquire clinical stage biopharmaceutical firm Imago BioSciences for US$1.35B; Imago is developing new medicines to treat myeloproliferative neoplasms and other bone marrow diseases

Oxfam America: Shareholder resolutions demand that Pfizer, Moderna, Merck, Johnson & Johnson address unequal access to COVID-19 vaccines and medicines

FDA reports Eli Lilly’s bebtelovimab not expected to neutralize new Omicron subvariants, although drug remains authorized for use in the US; FDA expects Pfizer’s Paxlovid, Gilead’s Veklury, Merck’s Lagevrio to remain effective against subvariants

Merck reports Q3 GAAP net income down 25% from a year ago at US$3.2B as sales increase 14% year-over-year to US$15.0B; results reflect sustained strong business momentum across key growth drivers, investment and progress in the pipeline

Merck grants Bill & Melinda Gates Medical Research Institute licenses for two preclinical antibacterial candidates for evaluation as components in affordable combination regimens to treat tuberculosis; TB causes an estimated 1.5 million deaths annually

Ask us about our R&D/Patents market view

Trending Chart

Interactive chart with headline count